TransCode enters $1.08M equity line with White Lion Capital for TTX-MC138 development

Transcode Therapeutics, Inc.

Up to $1.08M in common stock purchase agreement with White Lion Capital; proceeds for working capital and TTX-MC138 development.
Purchase price set at 92% of lower of 2-day VWAP or lowest closing price during valuation period.
Commitment period ends May 31, 2023; if less than 1.5M shares sold by then, company must deliver shares to White Lion.
Exchange cap of 3,163,124 shares (19.99% of outstanding) unless average price >= $0.39 or stockholder approval.
Shares offered under effective shelf registration statement (File No. 333-268764).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Transcode Therapeutics, Inc. entered into White Lion Purchase Agreement with White Lion Capital, LLC valued at up to $1,081,307 (effective 2023-04-13).

Action: entry
Agreement: equity purchase
Counterparty: White Lion Capital, LLC
Value: up to $1,081,307
Effective: 2023-04-13

Exact text from the filing

On April 13, 2023, TransCode Therapeutics, Inc. (the “Company”) entered into a Common Stock Purchase Agreement (the “White Lion Purchase Agreement”) with White Lion Capital, LLC, a Nevada limited liability company (“White Lion”).

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Transcode Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-045300

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.